Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

Éric Bruckert, Robert A. Hegele, Jan Albert Kuivenhoven et al. · European Heart Journal · 2014 · 1.1K citations · Full text

Medicine, Cardiology, Genetics +17

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Raúl D. Santos, Dirk Blom et al. · The Lancet · 2010 · 906 citations

Pharmacy, Pharmacology, Pharmacotherapy +16

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

Marina Cuchel, Emma A. Meagher, Hendrik du Toit Theron et al. · The Lancet · 2012 · 740 citations · Full text

Life Sciences, Pharmacokinetics, Pharmacology +12

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

Dirk Blom, Tomas Hala, Michael A. Bolognese et al. · New England Journal of Medicine · 2014 · 713 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Relation of Serum Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype to Coronary Heart Disease in Patients with Familial Hypercholesterolemia

Mary Seed, Fritz Hoppichler, D.A. Reaveley et al. · New England Journal of Medicine · 1990 · 591 citations · Full text

Medicine, Cardiology, Genetics +16